REG - PureTech Health PLC - Result of AGM

Puretech HealthAnnouncement

13/06/2024 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240613:nRSM3958Sa&default-theme=true

RNS Number : 3958S  PureTech Health PLC  13 June 2024

13 June 2024

PureTech Health plc

 

Results of Annual General Meeting

 

The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC)
("PureTech Health" or the "Company") was held at 11 a.m. EDT/4 p.m. BST on
Thursday, June 13, 2024.

 

All of the resolutions proposed at the Annual General Meeting were duly passed
by the shareholders on a poll. The results of the poll, incorporating the
proxy votes lodged in advance of the meeting, are set out below.

 

 Resolutions                                                                     For          %        Against     %       Withheld    Total votes cast
 001. To approve the Company's Annual Report and Accounts for year ended 31      180,831,234  100.00%  3,581       0.00%   90,476      180,834,815
 December 2023
 002. To approve the Directors' Remuneration Report                              72,296,583   55.95%   56,922,574  44.05%  51,706,134  129,219,157
 003. To approve the Directors' Remuneration Policy                              83,722,702   64.46%   46,157,643  35.54%  51,044,946  129,880,345
 004. To approve amendments to the rules of the PureTech Health plc Performance  91,600,947   70.74%   37,887,028  29.26%  51,437,316  129,487,975
 Share Plan 2023
 005. To elect Ms. Sharon Barber-Lui as a director                               180,223,191  99.99%   13,818      0.01%   688,282     180,237,009
 006. To elect Dr. Bharatt Chowrira as a director                                180,903,972  99.99%   14,250      0.01%   7,069       180,918,222
 007. To elect Dr. Raju Kucherlapati as a director                               168,304,704  93.03%   12,613,517  6.97%   7,070       180,918,221
 008. To elect Dr. John LaMattina as a director                                  97,660,582   74.71%   33,063,035  25.29%  50,201,674  130,723,617
 009. To elect Dr. Robert Langer as a director                                   178,992,250  98.94%   1,925,771   1.06%   7,270       180,918,021
 010. To elect Ms. Kiran Mazumdar-Shaw as a director                             171,626,767  94.91%   9,206,455   5.09%   92,069      180,833,222
 011. To reappoint PricewaterhouseCoopers LLP as Auditors of the Company         180,817,973  99.95%   95,238      0.05%   12,080      180,913,211
 012. To authorize the Audit Committee to determine the Auditors' remuneration   180,898,936  99.99%   20,477      0.01%   5,878       180,919,413
 013. To authorize the allotment of shares                                       168,771,484  97.85%   3,707,621   2.15%   8,446,186   172,479,105
 014. To disapply pre-emption rights                                             167,217,234  96.95%   5,261,591   3.05%   8,446,466   172,478,825
 015. To further disapply pre-emption rights for acquisitions and specified      165,299,824  95.84%   7,179,001   4.16%   8,446,466   172,478,825
 capital investments.
 016. To authorize market purchase of own shares                                 180,789,891  99.93%   129,498     0.07%   5,902       180,919,389
 017. To authorize general meetings to be called on not less than 14 clear       180,302,971  99.77%   422,112     0.23%   200,208     180,725,083
 days' notice

 

While the Board is pleased that all resolutions were supported by the required
majorities, we note that more than 20% of votes were cast against Resolutions
2, 3, 4 and 8. Over the past year, the Board has actively engaged with
shareholders regarding its approach to director remuneration, resulting in
adjustments to the proposed Remuneration Policy. Looking ahead, the Board will
continue to engage with shareholders to further understand their perspectives
and the reasons behind their opposition to certain proposals. In accordance
with the UK Corporate Governance Code, we will provide an update on our
engagement efforts within the next six months.

 

Notes:

 

(1)  A vote "Withheld" is not a vote in law and is not counted in the
calculation of the votes "For" or "Against" a resolution.

 

(2)  As at June 13, 2024 the number of issued shares in the Company was
270,859,250 ordinary shares, which was the total number of shares entitling
the holders to attend and vote for or against all the resolutions at the
AGM.  In accordance with the Company's Articles of Association, on a poll
every member present in person or by proxy has one vote for every share held.

 

(3)  The full text of the resolutions may be found in the Notice of the
Annual General Meeting, copies of which are available on both the Company's
website https://investors.puretechhealth.com/financials-filings/reports and on
the National Storage Mechanism.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and European
marketing authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates were
initially identified or discovered and then advanced by the PureTech team
through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statement that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation statements that relate to our expectations around
our therapeutic candidates and approach towards addressing major diseases, our
future prospects, developments, and strategies, and statements regarding the
intent, belief or current expectations regarding the Tender Offer. The
forward-looking statements are based on current expectations and are subject
to known and unknown risks, uncertainties and other important factors that
could cause actual results, performance and achievements to differ materially
from current expectations, including, but not limited to, those risks,
uncertainties and other important factors described under the caption "Risk
Factors" in our Annual Report on Form 20-F for the year ended December 31,
2023 filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only as at the
date of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information, future
events or otherwise.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGQKNBNABKDOAD